Page last updated: 2024-12-05
2-methylpyrrolidine
Description
2-Methylpyrrolidine is a cyclic secondary amine with a five-membered ring structure. It is a colorless liquid with a pungent odor and is soluble in water. It is used as a starting material for the synthesis of pharmaceuticals, pesticides, and other fine chemicals. 2-methylpyrrolidine is known to be a potent inhibitor of acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter involved in muscle contraction and memory. This property has led to research on its potential use as a therapeutic agent for Alzheimer's disease and other neurological disorders. 2-methylpyrrolidine is also a potent inhibitor of the enzyme monoamine oxidase, which is involved in the breakdown of neurotransmitters such as dopamine, norepinephrine, and serotonin. This property has led to research on its potential use as an antidepressant.'
2-methylpyrrolidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-methylpyrrolidine : A member of the class of pyrrolidines that is pyrrolidine which is substituted by a methyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 13003 |
CHEBI ID | 145240 |
MeSH ID | M0510280 |
Synonyms (35)
Synonym |
einecs 212-144-3 |
2-methylpyrrolidine |
pyrrolidine, 2-methyl- |
765-38-8 |
2-methylpyrrolidine, 96% |
2-methyl-pyrrolidine |
AKOS000157710 |
2-methyl pyrrolidine |
CHEBI:145240 |
A9699 |
BP-11381 |
FT-0646530 |
FT-0647960 |
FT-0600061 |
AM20100751 |
AKOS022175534 |
AB42774 |
2-methylpyrolidine |
rac.-2-methylpyrrolidine |
2-methyl-pyrolidine |
rac-2-methyl-pyrrolidine |
(2rs)-2-methylpyrrolidine |
2-(rs)-methylpyrrolidine |
racemic 2-methyl-pyrrolidine |
racemic 2-methylpyrrolidine |
(s)-2-methyl pyrrolidine |
r(-)-2-methyl-pyrrolidine |
W-104359 |
mfcd00014491 |
SY023070 |
W10111 |
DTXSID70883347 |
(2r)-2-methylpyrrolidinehydrochloride |
CS-0186674 |
EN300-49653 |
Roles (1)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
pyrrolidines | Any of a class of heterocyclic amines having a saturated five-membered ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 31.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 31.85 (24.57) | Research Supply Index | 2.08 (2.92) | Research Growth Index | 4.59 (4.65) | Search Engine Demand Index | 35.22 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |